Jeremy Pomeroy to Young Adult
This is a "connection" page, showing publications Jeremy Pomeroy has written about Young Adult.
Connection Strength
0.212
-
Pomeroy J, Mallya UG, Yang M, Huber C, Greatsinger A, Hagopian E, Haqq AM. Psychometric evaluation of novel hyperphagia questionnaires in a real-world setting for patients with a rare MC4R pathway disease. Orphanet J Rare Dis. 2025 Aug 22; 20(1):452.
Score: 0.107
-
Argente J, Haqq AM, Schorfheide JL, Touchot N, Huber C, Wiedemann U, Pomeroy J. Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity (Silver Spring). 2026 Mar; 34(3):579-587.
Score: 0.028
-
Cabre HE, Drews KL, Pomeroy J, Keadle SK, Arteaga SS, Franks PW, Haire-Joshu D, Knowler WC, Pi-Sunyer X, Van Horn L, Wing RR, Cahill AG, Clifton RG, Couch KA, Gallager D, Josefson JL, Joshipura K, Klein S, Martin CK, Peaceman AM, Phelan S, Thom EA, Redman LM. LIFE-Moms: effects of multicomponent lifestyle randomized control trial on physical activity during pregnancy in women with overweight and obesity. Int J Behav Nutr Phys Act. 2025 Sep 30; 22(1):119.
Score: 0.027
-
Shelton K, Dang P, McCorkle C, Mallipaddi P, Hollman N, Pomeroy J, Richards J. Congenital melanocytic nevi in Bardet-Biedl syndrome. Orphanet J Rare Dis. 2025 Aug 28; 20(1):462.
Score: 0.027
-
Lazareva J, Sisley SR, Brady SM, Smith ACM, Elsea SH, Pomeroy JJ, Roth CL, Sprague JE, Wabitsch M, Garrison J, Yanovski JA. Investigation of setmelanotide, an MC4R agonist, for obesity in individuals with Smith-Magenis syndrome. Obes Res Clin Pract. 2024 Jul-Aug; 18(4):301-307.
Score: 0.025